Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Alexander L Khokhlov"'
Autor:
Alexander L. Khokhlov, Ilya I. Yaichkov, Mikhail A. Alexeev, Mikhail K. Korsakov, Anton A. Shetnev, Sergey A. Ivanovsky, Nikita N. Volkhin, Sergey S. Petukhov, Elena A. Vasilyeva
Publikováno v:
Research Results in Pharmacology, Vol 10, Iss 2, Pp 83-95 (2024)
Introduction: 3-(2-butyl-5-chloro-1H-imidazole-4-yl)-N-[4-methoxy-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2-oxazole-5-carboxamide is new antirheumatic drug. It is necessary to identify and synthesize the biotransformation products for its complete p
Externí odkaz:
https://doaj.org/article/e7d6d2c823e64610b4e5e8e9f63e46e5
Autor:
Alexander L. Khokhlov, Ilya I. Yaichkov, Anton А. Shetnev, Sergey A. Ivanovsky, Mikhail K. Korsakov, Mikhail A. Alexeev, Olga A. Gasilina, Nikita N. Volkhin, Sergey S. Petukhov
Publikováno v:
Research Results in Pharmacology, Vol 10, Iss 1, Pp 53-66 (2024)
Introduction: The determination of biotransformation products is an essential part of the preclinical trial of original medicines. These studies have not been conducted before for the new drug 5-[5-(trifluoromethyl)-1,2-oxazole-3-yl]-furan-2-sulfonam
Externí odkaz:
https://doaj.org/article/ef728f4ae0304dd09e1dfd1d51e4a270
Autor:
Yulia R. Aleksandrova, Natalia S. Nikolaeva, Inna A. Shagina, Karina D. Smirnova, Alla A. Zubishina, Alexander I. Khlopotinin, Artem N. Fakhrutdinov, Alexander L. Khokhlov, Roman S. Begunov, Margarita E. Neganova
Publikováno v:
Molecules, Vol 29, Iss 22, p 5360 (2024)
The era of chemotherapy began in the 1940s, which is the basis of traditional antitumor approaches and, being one of the most high-tech treatment methods, is still widely used to treat various types of cancer. A promising direction in modern medicina
Externí odkaz:
https://doaj.org/article/4e19b94b8d9540198e0285d42a8652d3
Autor:
Alexander L. Khokhlov, Ilya I. Yaichkov, Mikhail K. Korsakov, Anton A. Shetnev, Nikita N. Volkhin, Sergey S. Petukhov
Publikováno v:
Research Results in Pharmacology, Vol 9, Iss 4, Pp 53-64 (2023)
Introduction: Development of new bioanalytical methods is required for studying the systemic exposure of new selective inhibitor of carbonic anhydrase II, 4-(2-methyl-1,3-oxazole-5-yl)-benzenesulfonamide, and its N-hydroxymetabolite in plasma and in
Externí odkaz:
https://doaj.org/article/cf39056d35dc4454954dfaf8461983aa
Publikováno v:
Research Results in Pharmacology, Vol 6, Iss 4, Pp 85-92 (2020)
Introduction: In modern clinical practice, various drug combinations are widely used, especially in cardiological patients. The existing clinical recommendations necessitate using organ protective agents, especially with a patient having a comorbid p
Externí odkaz:
https://doaj.org/article/629dae18143a41328f69cdae2360d349
Publikováno v:
Research Results in Pharmacology, Vol 6, Iss 3, Pp 21-26 (2020)
Introduction: The general requirements for assessing bioequivalence of endogenous drugs are described in the relevant guidelines, but they do not provide a complete picture of how to adequately develop a design of such a study. The aim of this articl
Externí odkaz:
https://doaj.org/article/a377bb2202764c91b09043d2bfd0cf69
Autor:
Alexander L. Khokhlov, Ilya I. Yaichkov, Yuriy A. Dzhurko, Leonid N. Shitov, Anastasia A. Shitova
Publikováno v:
Research Results in Pharmacology, Vol 4, Iss 1, Pp 33-42 (2018)
Introduction: This article describes the method development approaches for bioassay of substances containing unstable functional groups and forming unstable metabolites using the example of mycophenolic acid, methyldopa and mebeverine metabolites. M
Externí odkaz:
https://doaj.org/article/36ed75d3fc444517bc2618cad09cb053
Autor:
Victoria S, Kulesh, Roman V, Drai, Bella R, Zinnatulina, Igor E, Makarenko, Fedor G, Pilyus, Alexander L, Khokhlov
Publikováno v:
The Journal of Clinical Pharmacology. 62:1086-1093
This study includes modeling and simulation of insulin aspart pharmacokinetics (PK). The authors used PK data of biosimilar insulins-insulin aspart and biphasic insulin aspart 30/70-to develop a predictive population PK model for the insulins. The mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a23ffbb5f9e93ad0a1253879cfb341b4
https://doi.org/10.1002/jcph.2049
https://doi.org/10.1002/jcph.2049
Autor:
Maria V Verbovaya, Ivan S Lunev, Anna A Mosikian, Bella R Zinnatulina, Alexandr Y Mayorov, Diana N Alpenidze, Igor E. Makarenko, Roman V. Drai, Alexander L Khokhlov, Valeria L Orlova
Publikováno v:
Journal of Comparative Effectiveness Research. 10:55-66
Aim: To compare safety (immunogenicity) and efficacy of a biosimilar insulin GP-Lis25 and a reference insulin Ly-Lis25 (Humalog Mix 25) in Type 2 diabetes mellitus (T2D) patients. Materials & methods: This randomized open-label, 26-week clinical tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::906c65ee64499c9830107b39960acf29
https://doi.org/10.2217/cer-2020-0064
https://doi.org/10.2217/cer-2020-0064
Autor:
Svetlana T Zyangirova, Tatiana L Karonova, Tatiana M Belikova, Alexander L Khokhlov, Roman V. Drai, Alexander Yur'evich Mayorov, Igor E. Makarenko, Anna A Mosikian, Alsu Gafurovna Zalevskaya, Olena A Afonkina
Publikováno v:
Journal of Comparative Effectiveness Research. 9:263-273
Aim: To compare safety (immunogenicity) and efficacy of GP40061 insulin glargine (GP-Gla) and Lantus ® (Sanofi glargine, Sa-Gla) in people with diabetes mellitus. Materials & methods: This randomized open-label, 26-week clinical trial enrolled 180 T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::72fbd2b8d11ccd1222210a71e7fb4578
https://doi.org/10.2217/cer-2019-0136
https://doi.org/10.2217/cer-2019-0136